 BeiGene Ltd NASDAQ: BGNE revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa zanubrutinib to Johnson Johnsons NYSE: JNJ Imbruvica ibrutinib for relapsed or refractory RR chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. In the study, Brukinsa shrunk tumors in more patients than Imbruvica did while causing fewer incidents of a dangerous heart side effect. 